Furthermore, the relationships of both imaging outcomes with AD pathologies—not alpha-synuclein—suggest that patients with Lewy body diseases might stand to benefit from interventions directed against amyloid and tau pathologies. This evidence concerns the gene MAPT and Lewy body dementia.